Neucruit: Creating a platform to optimise participant recruitment for active COVID-19 vaccine trials, and future clinical and research trials.

临床研究试验保护患者免受实验性医学研究的影响，并确保新疫苗在规模化之前是安全有效的。平均而言，研究人员花费30%的研发资金来确保参与者的招募。当参与的标准很复杂时，可能需要长达7个月的时间才能找到参与者(CRM International-2011)。超过86%的临床研究由于参与者招募延迟而延迟长达6个月，对于需要救命治疗的患者来说，这意味着更长的延迟(应用临床试验-2004年)。为了了解新冠肺炎的性质、效果和抑制，需要进行广泛的试验。试验可能包括接种疫苗和无症状的患者测试，以了解疾病是如何传播的。大约有150项新冠肺炎疫苗试验正在等待检测，平均每项试验需要650名参与者(哈登-2018年)。世界各地的研究机构正试图紧急快速追踪疫苗。访问预先筛选的参与者网络将使疫苗接种成为现实，速度更快。Neucruit的创新结合了管理临床试验招募的优化平台，以及使用AI进行预选择和匹配的智能算法。Neucruit将通过基于网络的平台优化参与者招募，使临床研究人员与大量患者匹配，并将接触时间数字化以降低风险。在此项目中，我们将开发Neucruit平台到MVP，加入至少9,000名参与者，并在三个实时的第三阶段新冠肺炎疫苗接种试验中测试我们的软件。

Clinical research trials protect patients from experimental medical research and ensure that new vaccinations are safe and effective before they're scaled. On average, researchers spend 30% of R&D securing participant recruitment. When the criteria for participation is complex, it can take up to 7 months to find participants (CRM International-2011). Over 86% of clinical research is delayed by up to 6-months due to delays in participant recruitment, translating into even longer delays for patients who need life-saving treatments (Applied Clinical Trials-2004).To understand the nature, effects and suppression of COVID-19, extensive trials are needed. Trials are likely to include vaccinations and asymptomatic patient testing to understand how the disease is spread. There are approximately 150 COVID-19 vaccination trials awaiting testing, requiring on average 650 participants per trial (Harden-2018). Research facilities around the world are attempting to urgently fast-track a vaccine. Access to a network of pre-screened participants will make vaccinations a reality, quickly.Neucruit's innovation combines an optimised platform for managing recruitment of clinical trials, with intelligent algorithms for pre-selection and matching using AI.Neucruit will optimise participant recruitment via a web-based platform, which matchmakes clinical researchers with a large population of patients, and digitalises contact time for risk reduction.In this project we will develop the Neucruit platform to MVP, onboard a minimum 9,000 participants and test our software in three live Phase III COVID-19 vaccination trials.